Therefore, GAS5/miR-217/LHPP pathway reduces NSCLC cisplatin resistance and that LHPP may serve as a potential therapeutic target for NSCLC cisplatin resistance (Yang et al., 2021). The gene discussed is LHPP; the disease is non-small cell lung carcinoma.